When Glycaemic Control Comes Too Fast: Treatment‐Induced Neuropathy of Diabetes and Charcot Neuro‐Osteoarthropathy as Emerging Iatrogenic Complications of Rapid Metabolic Correction
Diabetes/Metabolism Research and Reviews · 2026-09 · 42 (6)
DOI: 10.1002/dmrr.70210 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 20.08.2026. Verfasst von Dured Dardari. Beteiligte Einrichtung: Diabetology Department, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France. Hauptthemen laut MEDLINE: Diabetic Neuropathies, Glycemic Control, Arthropathy, Neurogenic, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Purpose of Review Diabetes therapeutics can lower glycated haemoglobin (HbA1c) by several percentage points within weeks. While long‐term microvascular risk is reduced by improved glycaemia, abrupt metabolic transitions may destabilise tissues adapted to chronic hyperglycemia. We review treatment‐induced neuropathy of diabetes (TIND) and active Charcot neuro‐osteoarthropathy (CNO) as two neurovascular complications reported after rapid glycaemic correction, and we propose a unifying ‘metabolic tempo’ framework for prevention and early detection. Recent Findings TIND is an acute, painful small‐fibre and autonomic neuropathy occurring within 2–8 weeks after large HbA1c reductions, frequently coinciding with early worsening of retinopathy and nephropathy. Human in vivo nerve imaging demonstrates epineurial arteriovenous shunting and proliferative, leaky microvessels, supporting a microvascular dysregulation/ischaemia‐reperfusion model. For CNO, causal evidence linking rapid glycaemic improvement to disease onset remains limited and mainly observational; however, multiple case reports (including pregnancy, post‐transplantation, and major weight loss contexts) and retrospective cohorts suggest that major glycaemic ‘deceleration’ may cluster in the months preceding active CNO in susceptible patients with long‐standing neuropathy. Summary Rapid glycaemic correction should not be avoided when urgently needed, but ‘tempo‐aware’ strategies may be warranted in microvascularly fragile patients (very high baseline HbA1c, established neuropathy/retinopathy, kidney disease, or major weight loss). We outline pragmatic risk stratification, surveillance, and interdisciplinary pathways (neurology‐podiatry‐ophthalmology‐nephrology) to reduce delayed diagnosis and prevent deformity and disability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetology Department, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France.
- Laboratoire de Biologie de l'Exercice pour la Performance et la Santé, Université d'Evry, IRBA, Université Paris-Saclay, Evry, France.
- Kremlin Bicêtre Medical School, Université Paris-Saclay, Kremlin Bicetre, France.
ORCID-Profile: Dured Dardari
Zitieren
APA
Dardari, D. (2026). When Glycaemic Control Comes Too Fast: Treatment‐Induced Neuropathy of Diabetes and Charcot Neuro‐Osteoarthropathy as Emerging Iatrogenic Complications of Rapid Metabolic Correction. Diabetes/Metabolism Research and Reviews, 42(6). https://doi.org/10.1002/dmrr.70210
Vancouver
Dardari D. When Glycaemic Control Comes Too Fast: Treatment‐Induced Neuropathy of Diabetes and Charcot Neuro‐Osteoarthropathy as Emerging Iatrogenic Complications of Rapid Metabolic Correction. Diabetes/Metabolism Research and Reviews. 2026;42(6). doi:10.1002/dmrr.70210
BibTeX
@article{Dardari2026,
author = {Dardari, Dured},
title = {When Glycaemic Control Comes Too Fast: Treatment‐Induced Neuropathy of Diabetes and Charcot Neuro‐Osteoarthropathy as Emerging Iatrogenic Complications of Rapid Metabolic Correction},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2026},
volume = {42},
number = {6},
doi = {10.1002/dmrr.70210}
}
EUVIMED